G-CSF primed autologous marrow harvest and transplantation in cytapheresis ″mobilization failure″ patients

A descriptive analysis

G. L. Phillips, G. A. Hale, D. S. Howard, R. Nath, R. K. Munn, K. W. Marshall, D. E. Reece, Elizabeth Cecile Reed, G. Van Zant

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Fifteen cancer patients, deemed blood HSC ″mobilization failures″ due to CD34 + cell yields of <0.5x106/kg from two consecutive daily cytaphereses, underwent G-CSF primed autologous bone marrow harvest in an attempt to obtain adequate hematopoietic support for subsequent autotrans-plantation. CD34 + cell yields from the primed marrow harvest were variable; however, some patients had > 5-fold increases in CD34 + cell yields in the marrow compared to cytapheresis, and 4 patients had CD34 + cell yields of >1.0 (i.e., 1.2, 1.44, 1.61 and 2.45) x106/kg from the primed marrow harvest. None of the five patients previously exposed to stem cell toxins or fludarabine achieved > 0.85 x106/kg CD34 + cells with the primed marrow harvest. A significant difference was noted between G-CSF primed blood and marrow for CD34 + cells but not for GM-CFU (p = 0.011 and p = 0.135, respectively, paired t-test). All evaluable patients engrafted; a median ANC >0.5x109/L recovery was achieved on D + 12 (range + 9 to + 17) in 12 of 13 evaluable patients - one died on D + 9 without recovery. The last day of platelet transfusion occurred at a median D + 13 (range + 8 to>+66); only one patient remained platelet transfusion-dependent beyond D + 34. As anticipated, patients with higher numbers of CD34 + cells transplanted had somewhat more rapid recoveries. Although stem cell damage is obviously a key factor in mobilization failure patients, these findings raise the possibility that poor mobilization, at least in some patients, results from a mechanism other than, or in addition to, simple stem cell damage. Moreover, they raise the issue of the minimum number of marrow CD34 + - or more arguably other - cells needed for adequate short- and long-term reconstitution. The role of G-CSF in this situation, especially regarding dose and/or schedule, is intriguing but remains to be clarified. G-CSF primed marrow harvest is a potential option in certain poor mobilizers but, as fully expected, is frequently inadequate. Whether such is preferable to ″steady-state″ marrow harvest, continued or repeated G-CSF primed cytapheresis (with or without chemotherapy), or primed marrow with G-CSF in other schedules - or with other cytokines - is unclear and will be the subject of further study.

Original languageEnglish (US)
Pages (from-to)223-231
Number of pages9
JournalHematology
Volume5
Issue number3
DOIs
StatePublished - Jan 1 2000

Fingerprint

Cytapheresis
Granulocyte Colony-Stimulating Factor
Transplantation
Bone Marrow
Platelet Transfusion
Stem Cells
Appointments and Schedules
Granulocyte-Macrophage Progenitor Cells
Cell Count

Keywords

  • Autologous
  • Blood
  • G-CSF priming
  • Marrow
  • Stem cells
  • Transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Phillips, G. L., Hale, G. A., Howard, D. S., Nath, R., Munn, R. K., Marshall, K. W., ... Van Zant, G. (2000). G-CSF primed autologous marrow harvest and transplantation in cytapheresis ″mobilization failure″ patients: A descriptive analysis. Hematology, 5(3), 223-231. https://doi.org/10.1080/10245332.2000.11746511

G-CSF primed autologous marrow harvest and transplantation in cytapheresis ″mobilization failure″ patients : A descriptive analysis. / Phillips, G. L.; Hale, G. A.; Howard, D. S.; Nath, R.; Munn, R. K.; Marshall, K. W.; Reece, D. E.; Reed, Elizabeth Cecile; Van Zant, G.

In: Hematology, Vol. 5, No. 3, 01.01.2000, p. 223-231.

Research output: Contribution to journalArticle

Phillips, G. L. ; Hale, G. A. ; Howard, D. S. ; Nath, R. ; Munn, R. K. ; Marshall, K. W. ; Reece, D. E. ; Reed, Elizabeth Cecile ; Van Zant, G. / G-CSF primed autologous marrow harvest and transplantation in cytapheresis ″mobilization failure″ patients : A descriptive analysis. In: Hematology. 2000 ; Vol. 5, No. 3. pp. 223-231.
@article{e2fa82d580ed4e1ea6683109e0c83659,
title = "G-CSF primed autologous marrow harvest and transplantation in cytapheresis ″mobilization failure″ patients: A descriptive analysis",
abstract = "Fifteen cancer patients, deemed blood HSC ″mobilization failures″ due to CD34 + cell yields of <0.5x106/kg from two consecutive daily cytaphereses, underwent G-CSF primed autologous bone marrow harvest in an attempt to obtain adequate hematopoietic support for subsequent autotrans-plantation. CD34 + cell yields from the primed marrow harvest were variable; however, some patients had > 5-fold increases in CD34 + cell yields in the marrow compared to cytapheresis, and 4 patients had CD34 + cell yields of >1.0 (i.e., 1.2, 1.44, 1.61 and 2.45) x106/kg from the primed marrow harvest. None of the five patients previously exposed to stem cell toxins or fludarabine achieved > 0.85 x106/kg CD34 + cells with the primed marrow harvest. A significant difference was noted between G-CSF primed blood and marrow for CD34 + cells but not for GM-CFU (p = 0.011 and p = 0.135, respectively, paired t-test). All evaluable patients engrafted; a median ANC >0.5x109/L recovery was achieved on D + 12 (range + 9 to + 17) in 12 of 13 evaluable patients - one died on D + 9 without recovery. The last day of platelet transfusion occurred at a median D + 13 (range + 8 to>+66); only one patient remained platelet transfusion-dependent beyond D + 34. As anticipated, patients with higher numbers of CD34 + cells transplanted had somewhat more rapid recoveries. Although stem cell damage is obviously a key factor in mobilization failure patients, these findings raise the possibility that poor mobilization, at least in some patients, results from a mechanism other than, or in addition to, simple stem cell damage. Moreover, they raise the issue of the minimum number of marrow CD34 + - or more arguably other - cells needed for adequate short- and long-term reconstitution. The role of G-CSF in this situation, especially regarding dose and/or schedule, is intriguing but remains to be clarified. G-CSF primed marrow harvest is a potential option in certain poor mobilizers but, as fully expected, is frequently inadequate. Whether such is preferable to ″steady-state″ marrow harvest, continued or repeated G-CSF primed cytapheresis (with or without chemotherapy), or primed marrow with G-CSF in other schedules - or with other cytokines - is unclear and will be the subject of further study.",
keywords = "Autologous, Blood, G-CSF priming, Marrow, Stem cells, Transplantation",
author = "Phillips, {G. L.} and Hale, {G. A.} and Howard, {D. S.} and R. Nath and Munn, {R. K.} and Marshall, {K. W.} and Reece, {D. E.} and Reed, {Elizabeth Cecile} and {Van Zant}, G.",
year = "2000",
month = "1",
day = "1",
doi = "10.1080/10245332.2000.11746511",
language = "English (US)",
volume = "5",
pages = "223--231",
journal = "Hematology",
issn = "1024-5332",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - G-CSF primed autologous marrow harvest and transplantation in cytapheresis ″mobilization failure″ patients

T2 - A descriptive analysis

AU - Phillips, G. L.

AU - Hale, G. A.

AU - Howard, D. S.

AU - Nath, R.

AU - Munn, R. K.

AU - Marshall, K. W.

AU - Reece, D. E.

AU - Reed, Elizabeth Cecile

AU - Van Zant, G.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Fifteen cancer patients, deemed blood HSC ″mobilization failures″ due to CD34 + cell yields of <0.5x106/kg from two consecutive daily cytaphereses, underwent G-CSF primed autologous bone marrow harvest in an attempt to obtain adequate hematopoietic support for subsequent autotrans-plantation. CD34 + cell yields from the primed marrow harvest were variable; however, some patients had > 5-fold increases in CD34 + cell yields in the marrow compared to cytapheresis, and 4 patients had CD34 + cell yields of >1.0 (i.e., 1.2, 1.44, 1.61 and 2.45) x106/kg from the primed marrow harvest. None of the five patients previously exposed to stem cell toxins or fludarabine achieved > 0.85 x106/kg CD34 + cells with the primed marrow harvest. A significant difference was noted between G-CSF primed blood and marrow for CD34 + cells but not for GM-CFU (p = 0.011 and p = 0.135, respectively, paired t-test). All evaluable patients engrafted; a median ANC >0.5x109/L recovery was achieved on D + 12 (range + 9 to + 17) in 12 of 13 evaluable patients - one died on D + 9 without recovery. The last day of platelet transfusion occurred at a median D + 13 (range + 8 to>+66); only one patient remained platelet transfusion-dependent beyond D + 34. As anticipated, patients with higher numbers of CD34 + cells transplanted had somewhat more rapid recoveries. Although stem cell damage is obviously a key factor in mobilization failure patients, these findings raise the possibility that poor mobilization, at least in some patients, results from a mechanism other than, or in addition to, simple stem cell damage. Moreover, they raise the issue of the minimum number of marrow CD34 + - or more arguably other - cells needed for adequate short- and long-term reconstitution. The role of G-CSF in this situation, especially regarding dose and/or schedule, is intriguing but remains to be clarified. G-CSF primed marrow harvest is a potential option in certain poor mobilizers but, as fully expected, is frequently inadequate. Whether such is preferable to ″steady-state″ marrow harvest, continued or repeated G-CSF primed cytapheresis (with or without chemotherapy), or primed marrow with G-CSF in other schedules - or with other cytokines - is unclear and will be the subject of further study.

AB - Fifteen cancer patients, deemed blood HSC ″mobilization failures″ due to CD34 + cell yields of <0.5x106/kg from two consecutive daily cytaphereses, underwent G-CSF primed autologous bone marrow harvest in an attempt to obtain adequate hematopoietic support for subsequent autotrans-plantation. CD34 + cell yields from the primed marrow harvest were variable; however, some patients had > 5-fold increases in CD34 + cell yields in the marrow compared to cytapheresis, and 4 patients had CD34 + cell yields of >1.0 (i.e., 1.2, 1.44, 1.61 and 2.45) x106/kg from the primed marrow harvest. None of the five patients previously exposed to stem cell toxins or fludarabine achieved > 0.85 x106/kg CD34 + cells with the primed marrow harvest. A significant difference was noted between G-CSF primed blood and marrow for CD34 + cells but not for GM-CFU (p = 0.011 and p = 0.135, respectively, paired t-test). All evaluable patients engrafted; a median ANC >0.5x109/L recovery was achieved on D + 12 (range + 9 to + 17) in 12 of 13 evaluable patients - one died on D + 9 without recovery. The last day of platelet transfusion occurred at a median D + 13 (range + 8 to>+66); only one patient remained platelet transfusion-dependent beyond D + 34. As anticipated, patients with higher numbers of CD34 + cells transplanted had somewhat more rapid recoveries. Although stem cell damage is obviously a key factor in mobilization failure patients, these findings raise the possibility that poor mobilization, at least in some patients, results from a mechanism other than, or in addition to, simple stem cell damage. Moreover, they raise the issue of the minimum number of marrow CD34 + - or more arguably other - cells needed for adequate short- and long-term reconstitution. The role of G-CSF in this situation, especially regarding dose and/or schedule, is intriguing but remains to be clarified. G-CSF primed marrow harvest is a potential option in certain poor mobilizers but, as fully expected, is frequently inadequate. Whether such is preferable to ″steady-state″ marrow harvest, continued or repeated G-CSF primed cytapheresis (with or without chemotherapy), or primed marrow with G-CSF in other schedules - or with other cytokines - is unclear and will be the subject of further study.

KW - Autologous

KW - Blood

KW - G-CSF priming

KW - Marrow

KW - Stem cells

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0033785851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033785851&partnerID=8YFLogxK

U2 - 10.1080/10245332.2000.11746511

DO - 10.1080/10245332.2000.11746511

M3 - Article

VL - 5

SP - 223

EP - 231

JO - Hematology

JF - Hematology

SN - 1024-5332

IS - 3

ER -